Literature DB >> 29243072

Volume-based glucose metabolic analysis of FDG PET/CT: The optimum threshold and conditions to suppress physiological myocardial uptake.

Osamu Manabe1, Markus Kroenke2,3, Tadao Aikawa4, Atsuto Murayama2, Masanao Naya4, Atsuro Masuda5, Noriko Oyama-Manabe6, Kenji Hirata2, Shiro Watanabe2, Tohru Shiga2, Chietsugu Katoh7, Nagara Tamaki2,8.   

Abstract

OBJECTIVE: FDG PET/CT plays a significant role in the diagnosis of inflammatory heart diseases and cardiac tumors. We attempted to determine the optimal FDG uptake threshold for volume-based analyses and to evaluate the relationship between the myocardial physiological uptake volume in FDG PET and several clinical factors.
METHODS: A total of 190 patients were retrospectively analyzed. The cardiac metabolic volume (CMV) was defined as a volume within the boundary determined by a threshold (SUVmean of blood pool × 1.5).
RESULTS: The SUVmean of the blood pool measured in the descending aorta (DA) (r = 0.86, intraclass correlation coefficient [ICC] = 0.93, P < 0.0001) and that in the left ventricle (LV) cavity (r = 0.87, ICC = 0.90, P < 0.0001) showed high inter-operator reproducibility. However, the SUVmean in the LV cavity showed a significant correlation with the CMV (P = 0.0002, r = 0.26). The CMV in the patients who fasted < 18 hours were significantly higher (49.7  ±  73.2 vs. 18.0  ±  53.8 mL, P = 0.0013) compared to the patients with > 18-hour fasting. The multivariate analysis demonstrated that only the fasting period > 18 hours was independently associated with CMV = 0.
CONCLUSION: Our findings revealed that the DA is suitable to decide the threshold for the volume-based analysis. The fasting time was significantly associated with the cardiac FDG uptake.

Entities:  

Keywords:  18F-Fluorodeoxyglucose; Metabolism: PET; PET; fasting; physiological uptake

Year:  2017        PMID: 29243072     DOI: 10.1007/s12350-017-1122-6

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  20 in total

1.  Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis.

Authors:  Azadeh Ahmadian; Ashley Brogan; Jeffrey Berman; Aaron L Sverdlov; Gustavo Mercier; Michael Mazzini; Praveen Govender; Frederick L Ruberg; Edward J Miller
Journal:  J Nucl Cardiol       Date:  2014-05-31       Impact factor: 5.952

2.  PET/CT quantitation of the effect of patient-related factors on cardiac 18F-FDG uptake.

Authors:  Ora Israel; Michal Weiler-Sagie; Shmuel Rispler; Rachel Bar-Shalom; Alex Frenkel; Zohar Keidar; Avi Bar-Shalev; H William Strauss
Journal:  J Nucl Med       Date:  2007-02       Impact factor: 10.057

3.  Inter- and Intraobserver Agreement of 18F-FDG PET/CT Image Interpretation in Patients Referred for Assessment of Cardiac Sarcoidosis.

Authors:  Hiroshi Ohira; Brian Mc Ardle; Robert A deKemp; Pablo Nery; Daniel Juneau; Jennifer M Renaud; Ran Klein; Owen Clarkin; Karen MacDonald; Eugene Leung; Girish Nair; Rob Beanlands; David Birnie
Journal:  J Nucl Med       Date:  2017-03-02       Impact factor: 10.057

4.  Evaluation of the relationship between physiological FDG uptake in the heart and age, blood glucose level, fasting period, and hospitalization.

Authors:  Tomohiro Kaneta; Takashi Hakamatsuka; Kentaro Takanami; Takayuki Yamada; Kei Takase; Akihiro Sato; Shuichi Higano; Shigeo Kinomura; Hiroshi Fukuda; Shoki Takahashi; Shogo Yamada
Journal:  Ann Nucl Med       Date:  2006-04       Impact factor: 2.668

Review 5.  The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience.

Authors:  George Youssef; Eugene Leung; Ilias Mylonas; Pablo Nery; Kathryn Williams; Gerald Wisenberg; Karen Y Gulenchyn; Robert A Dekemp; Jean Dasilva; David Birnie; George A Wells; Rob S B Beanlands
Journal:  J Nucl Med       Date:  2012-01-06       Impact factor: 10.057

6.  Hepatic steatosis is associated with increased hepatic FDG uptake.

Authors:  Georgia Keramida; Jon Potts; Janice Bush; Sabina Dizdarevic; A Michael Peters
Journal:  Eur J Radiol       Date:  2014-02-07       Impact factor: 3.528

7.  Administration of unfractionated heparin with prolonged fasting could reduce physiological 18F-fluorodeoxyglucose uptake in the heart.

Authors:  Atsuro Masuda; Masanao Naya; Osamu Manabe; Keiichi Magota; Keiichiro Yoshinaga; Hiroyuki Tsutsui; Nagara Tamaki
Journal:  Acta Radiol       Date:  2015-09-02       Impact factor: 1.990

8.  Reduction in ¹⁸F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis.

Authors:  Michael T Osborne; Edward A Hulten; Avinainder Singh; Alfonso H Waller; Marcio S Bittencourt; Garrick C Stewart; Jon Hainer; Venkatesh L Murthy; Hicham Skali; Sharmila Dorbala; Marcelo F Di Carli; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2013-12-03       Impact factor: 5.952

9.  Visual findings of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with cardiac sarcoidosis.

Authors:  Kimiteru Ito; Osamu Okazaki; Miyako Morooka; Kazuo Kubota; Ryogo Minamimoto; Michiaki Hiroe
Journal:  Intern Med       Date:  2014-09-15       Impact factor: 1.271

10.  Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis.

Authors:  Miyako Morooka; Masao Moroi; Kimiichi Uno; Kimiteru Ito; Jin Wu; Takashi Nakagawa; Kazuo Kubota; Ryogo Minamimoto; Yoko Miyata; Momoko Okasaki; Osamu Okazaki; Yoshihito Yamada; Tetsuo Yamaguchi; Michiaki Hiroe
Journal:  EJNMMI Res       Date:  2014-01-02       Impact factor: 3.138

View more
  7 in total

Review 1.  Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update: Japanese Society of Nuclear Cardiology recommendations.

Authors:  Shinichiro Kumita; Keiichiro Yoshinaga; Masao Miyagawa; Mitsuru Momose; Keisuke Kiso; Tokuo Kasai; Masanao Naya
Journal:  J Nucl Cardiol       Date:  2019-08       Impact factor: 5.952

2.  Value of simultaneous assessment of cardiac functions by PET/MRI.

Authors:  Nagara Tamaki; Shigenori Matsushima; Motoki Nishimura
Journal:  J Nucl Cardiol       Date:  2018-07-20       Impact factor: 5.952

3.  Does simplified quantitative analysis of 18F-FDG PET in cardiac inflammatory disease work?

Authors:  R Nkoulou; H Zaidi
Journal:  J Nucl Cardiol       Date:  2018-01-17       Impact factor: 5.952

4.  Use of 18F-FDG PET/CT texture analysis to diagnose cardiac sarcoidosis.

Authors:  Osamu Manabe; Hiroshi Ohira; Kenji Hirata; Souichiro Hayashi; Masanao Naya; Ichizo Tsujino; Tadao Aikawa; Kazuhiro Koyanagawa; Noriko Oyama-Manabe; Yuuki Tomiyama; Keiichi Magota; Keiichiro Yoshinaga; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-16       Impact factor: 9.236

5.  Association of high serum soluble interleukin 2 receptor levels with risk of adverse events in cardiac sarcoidosis.

Authors:  Yuta Kobayashi; Takuma Sato; Toshiyuki Nagai; Kenji Hirata; Satonori Tsuneta; Yoshiya Kato; Hirokazu Komoriyama; Kiwamu Kamiya; Takao Konishi; Kazunori Omote; Hiroshi Ohira; Kohsuke Kudo; Satoshi Konno; Toshihisa Anzai
Journal:  ESC Heart Fail       Date:  2021-09-12

6.  Which is the proper reference tissue for measuring the change in FDG PET metabolic volume of cardiac sarcoidosis before and after steroid therapy?

Authors:  Sho Furuya; Osamu Manabe; Hiroshi Ohira; Kenji Hirata; Tadao Aikawa; Masanao Naya; Ichizo Tsujino; Kazuhiro Koyanagawa; Toshihisa Anzai; Noriko Oyama-Manabe; Tohru Shiga
Journal:  EJNMMI Res       Date:  2018-10-05       Impact factor: 3.138

Review 7.  Advances in Diagnostic Imaging for Cardiac Sarcoidosis.

Authors:  Osamu Manabe; Noriko Oyama-Manabe; Tadao Aikawa; Satonori Tsuneta; Nagara Tamaki
Journal:  J Clin Med       Date:  2021-12-11       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.